Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

Tumor mutation load (TML) has been proposed as a biomarker of patient response to immunotherapy in several studies. TML is usually determined by tumor biopsy DNA (tDNA) whole exome sequencing (WES), therefore TML evaluation is limited by informative biopsy availability. Circulating cell free DNA (cf...

Full description

Bibliographic Details
Main Authors: Florence Koeppel, Steven Blanchard, Cécile Jovelet, Bérengère Genin, Charles Marcaillou, Emmanuel Martin, Etienne Rouleau, Eric Solary, Jean-Charles Soria, Fabrice André, Ludovic Lacroix
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5697854?pdf=render

Internet

http://europepmc.org/articles/PMC5697854?pdf=render

Similar Items